Prothionamide is a thioamide-class antimycobacterial agent used as part of combination regimens for tuberculosis and leprosy; Protionamide is a medication used in the treatment of tuberculosis and leprosy. Protionamide is a therapeutic alternative on the World Health Organization's List of Essential Medicines. Chemically related to ethionamide, prothionamide is active against Mycobacterium species after enzymatic activation in the bacillus, and it is employed clinically for patients with drug resistant or difficult to treat mycobacterial infections or when first line agents are contraindicated. The active substance is formulated for oral administration, characterized by good oral bioavailability, and is handled and assayed under controlled pharmaceutical manufacturing conditions to ensure potency and stability. Analytical control typically includes identity testing, assay by validated chromatographic methods, dissolution for finished forms, and stress testing to define degradation pathways and storage recommendations.
Parent: Prothionamide
Typical pharmaceutical specifications monitor related substances, degradation products and residual process impurities using validated high performance liquid chromatography and mass spectrometry methods; a representative specification for the active pharmaceutical ingredient used by manufacturers includes assay within accepted limits and impurity controls where individual unidentified impurities are commonly limited to approximately 0.1 to 0.2 percent by weight and total impurities are controlled to approximately 0.5 percent by weight or below, depending on the monograph or company specification. Known related compounds and degradants that are targeted in control strategies include process-related analogs, oxidative sulfoxide species, and minor hydrolytic products, while residual solvents and heavy metals are controlled to ICH Q3C and elemental impurity guidelines respectively. Stability profiling under heat, humidity, light and oxidative stress defines shelf life and recommended packaging to minimize formation of these impurities.
Prothionamide is a thioamide prodrug that requires activation by mycobacterial enzymes to form an active metabolite that inhibits the enoyl acyl carrier protein reductase involved in mycolic acid biosynthesis, disrupting cell wall formation and exerting bacteriostatic to bactericidal effects against susceptible mycobacteria.
Prothionamide tablets are used orally as part of combination therapy for pulmonary and extrapulmonary tuberculosis and for treatment of leprosy when indicated, particularly in cases of drug resistance or intolerance to first line agents; they are not recommended as monotherapy and dosing and combination partners are defined by national and international tuberculosis treatment guidelines.
